One tool doctors use is called the Crohn’s Disease Activity Index (CDAI). A CDAI score is based on the severity of various symptoms over seven days. Those symptoms include things such as ...

The following is a summary of “Patients with PSOriasis and Suppurative Hidradenitis (PSO-SH) share genetic risk factors and are at risk of increased morbidity.,” published in the February 2025 issue ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

INTERCEPT will recruit 10,000 healthy first-degree relatives of individuals with Crohn's disease from seven European countries to validate biomarkers and risk score. Of these, 80 people at the ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

A special liquid diet, known as exclusive enteral nutrition, is an essential therapy for Crohn's disease. Patients consume only this formula for six to eight weeks, completely avoiding solid foods.

Endoscopic response was defined as >50% reduction from baseline in Simple Endoscopic Score for Crohn's disease (SES-CD) total score, based on central reading. Bowel urgency was also assessed with ...

Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

The results of the RELIEVE UCCD study in patients with moderate-to-severe ulcerative colitis (UC) and Crohn's disease suggest a "best-in-class potential" for the drug, which Sanofi licensed from ...

Takeda and the EU’s Innovative Health Initiative have announced a €‎38m project aimed at improving early intervention in Crohn’s disease. The “first-of-its-kind” INTERCEPT study will use biomarkers to ...